Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer

JAMA Dermatol. 2016 Mar;152(3):340-2. doi: 10.1001/jamadermatol.2015.4448.

Authors

Kai-Lung Chen¹, Chia-Chi Lin², Yung-Tsu Cho¹, Che-Wen Yang¹, Yi-Shuan Sheen¹, Hsiao-En Tsai³, Chia-Yu Chu¹

Affiliations

¹ Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei.
² Department of Oncology, National Taiwan University Hospital, Taipei3Department of Urology, National Taiwan University College of Medicine, Taipei.
³ Department of Surgery, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu City.

PMID: 26649681
DOI: 10.1001/jamadermatol.2015.4448

No abstract available

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Acneiform Eruptions / chemically induced
Acneiform Eruptions / epidemiology
Afatinib
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Cohort Studies
Compassionate Use Trials
Cross-Sectional Studies
Drug Eruptions / diagnosis*
Drug Eruptions / etiology*
Erlotinib Hydrochloride / adverse effects*
Erlotinib Hydrochloride / therapeutic use
Gefitinib
Humans
Ichthyosis / chemically induced
Ichthyosis / epidemiology
Lung Neoplasms / drug therapy*
Paronychia / chemically induced
Paronychia / epidemiology
Pruritus / chemically induced
Pruritus / epidemiology
Quinazolines / adverse effects*
Quinazolines / therapeutic use
Retrospective Studies

Substances

Quinazolines
Afatinib
Erlotinib Hydrochloride
Gefitinib